Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.

BMC molecular biology - 7 Mar 2012

Fiszer Agnieszka, Olejniczak Marta, Switonski Pawel M, Wroblewska Joanna P, Wisniewska-Kruk Joanna, Mykowska Agnieszka, Krzyzosiak Wlodzimierz J

Abstract excerpt

BACKGROUND: RNA interference (RNAi) and antisense strategies provide experimental therapeutic agents for numerous diseases, including polyglutamine (polyQ) disorders caused by CAG repeat expansion. We compared the potential of different oligonucleotide-based strategies for silencing the genes responsible for several polyQ diseases, including Huntington's disease and two spinocerebellar ataxias, type 1 and type 3....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxin-3
Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Silencing

Share to Genetic Therapy

Share to Huntingtin Protein

Share to Huntington Disease

Share to Oligonucleotides

Share to Spinocerebellar Ataxias

Source

Open in PubMed Open full text

Identifiers

PMID: 22397573
DOI: 10.1186/1471-2199-13-6
PMCID: PMC3359213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.PMID 22397573Read ↗

Oligonucleotide-based strategies to combat polyglutamine diseases.Semantic proximity Read ↗

Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disordersSemantic proximity Read ↗

Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative DiseasesSemantic proximity Read ↗

Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense TherapiesSemantic proximity Read ↗

Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine DiseasesSemantic proximity Read ↗

Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disordersSemantic proximity Read ↗

Allele-selective suppression of mutant genes in polyglutamine diseases.Semantic proximity Read ↗

Antisense oligonucleotides and other genetic therapies made simpleSemantic proximity Read ↗

Gene-targeting pharmaceuticals for single-gene disordersSemantic proximity Read ↗

Polyglutamine (PolyQ) Diseases: Genetics to TreatmentsSemantic proximity Read ↗

Limits of using oligonucleotides for allele-selective inhibition at trinucleotide repeat sequences - targeting the CAG repeat within ataxin-1.Semantic proximity Read ↗

Therapeutic gene silencing strategies for polyglutamine disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.